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Abstract
Background To evaluate retinal ganglion cell
(RGC) function after intraocular pressure (IOP)
reduction measured by pattern electroretinogram
(PERG) in patients with newly diagnosed, non-treated
preperimetric and early stages of primary open-angle
glaucoma (POAG).
Methods Twenty-four eyes from 24 patients with
POAG: 11 eyes with preperimetric glaucoma and 13
eyes with early glaucoma received Ganfort (bimato-
prost ? timolol) once a day for a period of 1 month.
Before and after the treatment, following measure-
ments were analyzed: IOP, mean ocular perfusion
pressure (MOPP), peak time of P50 and amplitude of
P50 and N95 waves in PERG (ISCEV standard 2012).
Correlations between PERG P50 and N95 waves, IOP
and MOPP were calculated.
Results After therapy, IOP significantly decreased in
all eyes, on average 31%. Significant increase in
MOPP in all eyes on average 14% was detected. PERG
amplitude of P50 and N95 waves increased in 75 and
79% eyes, respectively, on average P50 by 28% and
N95 by 38%. There were no significant interactions
between the change of PERG parameters in time and
stage of glaucoma.
Conclusions Significant IOP-lowering therapy can
improve RGC function measured by PERG, in patients
with preperimetric and early stages of POAG.
Keywords POAG treatment  Retinal ganglion cell
function  Pattern electroretinogram
Introduction
Glaucoma is described as an optic neuropathy, in
which retinal ganglion cells (RGCs) degenerate and, in
consequence, a progressive loss of vision can occur
[1]. For many years, glaucomatous damage of the
optic nerve was considered irreversible, but as many
research results show, this theory is false: appropriate
therapy lowering intraocular pressure (IOP) can
improve not only changes in the visual field [2], but
also the function of RGC, which can be measured by
electrophysiological tests, such as pattern elec-
troretinogram (PERG) [3] or PERG optimized for
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glaucoma screening (PERGLA) [4]. It is well known
that the optimal IOP reduction depends on the degree
of visual field damage at diagnosis and the rate of
progression [1]. There is no single and safe IOP level.
It varies between patients and eyes. That is why the
‘target IOP’ is the highest IOP expected to prevent
further glaucomatous damage or slow down disease
progression to a minimum [1].
Dietlein et al. [5] tried to evaluate the percentage of
IOP that should be reduced from its baseline value.
They recommend a reduction by 20–50%, depending
on the degree of existing damage, the baseline IOP, the
rate of progression and, finally, patient’s age. Accord-
ing to their review, topical monotherapy can decrease
IOP between 15 and 30%, while IOP reduction
observed after incisional glaucoma surgery ranges
from 50 to 90%. However, we still do not know how
much IOP should be decreased in order to improve
RGC function.
A clinical trial published in 2011 by Sehi et al. [6]
tried to evaluate the impact of IOP reduction on RGC
function in glaucoma suspect and glaucomatous eyes
receiving latanoprost 0.005%, using PERGLA. This
prospective trial did not reveal significant changes in
PERGLA amplitude after therapy, with either latano-
prost or placebo. According to authors, one of the most
important reasons of such results is that mean reduc-
tion in IOP after latanoprost (20 ± 13%) was insuf-
ficient to improve the signal generated by RGC.
The results of another study performed by Sehi
et al. [7] made likely that after surgical reduction in
IOP (which was about 47%), reversal of RGC
dysfunction occurs and may be quantified using
PERGLA.
That is why we presumed that, to improve the RGC
function, IOP should be decreased 30% or more.
Although there are no clear guidelines which group
of medications should be the first choice treatment,
prostaglandin analogs are often used as the first choice
drugs, because they are effective, comfortable in using
(once daily) and have a minimal risk of hyperemia.
However, many patients require more than one
medication to achieve target IOP. Nowadays, the most
commonly used drug added to prostaglandins is a beta-
blocker, such as timolol [8].
According to a meta-analysis [8], evaluating the
IOP-lowering effects and tolerability of the three
prostaglandin–timolol fixed combinations (PG–ti-
molol FCs), IOP reduction was significantly greater
with bimatoprost–timolol FC, compared to latano-
prost–timolol FC and travoprost–timolol FC. The
incidence of hyperemia was not significantly lower
with latanoprost–timolol FC than with bimatoprost–
timolol FC.
It seemed sensible to hypothesize that Ganfort
(Allergan Pharmaceuticals Ireland), which contains
bimatoprost (0.3 mg/ml) and timolol maleate (5 mg/
ml), could be the medication that will improve RGC
function, because it reduces IOP by 35.1% [9].
The clinical significance of a 30% IOP reduction is
based on observation from major trials [10–14] as well
as on new glaucoma guidelines [15]. This reduction
can stop the progression of glaucoma neuropathy. The
aim of this study was to evaluate the influence of
recommended IOP reduction on RGC function, mea-
sured by PERG in eyes of patients with non-treated
preperimetric or early stages of primary open-angle
glaucoma (POAG). We could expect that, in these
stages of disease, RGCs are not only apoptotic and/or
with structural changes, but some are just dysfunc-
tional [16]. By lowering IOP, we may restore RGC
function and prevent apoptosis [17]. The transient
PERG was used to check whether this commonly used
stimulation is enough sensitive to monitor changes of
RGC function after IOP-lowering therapy.
Methods
Subjects
Twenty-four eyes from 24 patients aged
56 ± 11 years with newly diagnosed preperimetric
or early stages of POAG, without previous treatment,
were enrolled in the study. They were recruited from
ophthalmological outpatient departments. The
preperimetric POAG was diagnosed, according to
actual criteria: a glaucomatous appearance of the optic
disc head, open chamber angle, and thinning of retinal
nerve fiber layer (RNFL) thickness, measured by
scanning laser polarimetry (GDx) or optical coherence
tomography (OCT), with normal visual field (VF),
confirmed by at least two following standard auto-
mated perimetry (SAP) (HFA 24-2 W-W/SITA stan-
dard strategy) examinations [18]. The early stage of
POAG was diagnosed, according to the European
Glaucoma Society, on the basis of SAP, and each SAP
was repeated once to confirm VF abnormalities. All
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patients underwent a complete ophthalmic examina-
tion: distance best-corrected visual acuity (DBCVA)
using logMAR-ETDRS chart, slit lamp biomi-
croscopy, gonioscopy, Pascal applanation tonometry,
dilated stereoscopic fundus examination (VOLK 90)
and PERG. Blood pressure (BP) of all patients was
measured with the use of a blood pressure device to
calculate mean ocular perfusion pressure (MOPP),
defined as the difference between 2/3 mean arterial
pressure (MAP) and IOP.
All abovementioned examinations were performed
twice: before treatment and 1 month after Ganfort
instillation every day at 7 p.m. Patients’ characteris-
tics are shown in Table 1.
Exclusion criteria were as follows: DBCVA\0.15,
corneal/retinal pathology, age \35 or [75, prior
intraocular surgery (except for uncomplicated cataract
surgery), unreliable SAP ([33% rate of fixation loses),
contraindications to bimatoprost and/or timolol and/or
PERG, ocular or systemic disease with a known
influence on retinal function (ex. diabetes mellitus,
dementive diseases) at the time of diagnosis or
throughout the follow-up.
This project was authorized by the Local Ethical
Committee of the Pomeranian Medical University in
Szczecin. An informed written consent was obtained
from all subjects after the purpose of the study, and
possible risks were clarified.
Electroretinography
Transient PERG was recorded with the RetiPort
(Roland Consult GmbH, Germany) system according
to the ISCEV standard 2013 [19]. Monocular
stimulation was used without pupil dilation; refraction
correction was applied with respect to the eye-screen
distance. Central fixation was used. The patient was
monitored with a TV camera, and interruptions of the
test were introduced when fixation loss or frequent
blinking was observed. 2100 CRT monitor with a frame
rate of 70 fps was used for pattern stimulation;
dimension of the stimulus field was 15240 (the mean
of the width and the height of the screen), with the
aspect ratio between the width and the height (screen
proportion H/V) equal to 4:3; black and white
reversing checkerboard was presented to the patient,
with a check size equal to 0480; luminance for white
elements was equal to 118 cd/m2, mean luminance of
the stimulus screen: 60 cd/m2, with Michelson con-
trast set to 97%; and temporal frequency was equal to
4.0 rps (2.0 Hz). Thread DTL-like electrode (Roland
Consult) was used as active, gold disc (Grass, USA)
skin electrode was placed at the ipsilateral outer
canthus as reference, and ground (gold disc, Grass)
electrode was placed on the forehead (Fpz). Parame-
ters of the recording channel were as follows: ampli-
fiers sensitivity 20 lV/div, filter frequency bandwidth
1–100 Hz. The analysis period (sweep time) was equal
to 250 ms. Artifact rejection threshold was set to 95%
(for the amplifiers range ±100 lV), and 200 sweeps
were averaged. For each eye, two consecutive PERG
waveforms were recorded and off-line averaged for
further analysis. According to the standard, amplitude
of P50 and N95 waves, as well as peak time of P50
wave were analyzed. Values of all parameters were
compared with the laboratory own normal values.
The first author had good experience in using DTL
electrode for PERG recording.
Table 1 Groups characteristic: preperimetric and early-stage POAG
Stage of glaucoma Trait n Mean SD Min Max
Early Age (y) 13 61.2 8.06 39.0 72.0
DBCVA (logMAR) 13 0.05 0.06 0.15 0.00
IOP1 (mmHg) 13 24.57 6.48 15.90 37.20
MOPP1 13 42.99 9.81 25.38 57.87
Preperimetric Age (y) 11 50.64 12.44 22.00 66.00
DBCVA (logMAR) 11 0.06 0.06 0.15 0.00
IOP1 (mmHg) 11 23.90 4.98 16.90 34.90
MOPP1 11 41.66 6.20 28.98 47.63
DBCVA distance best-corrected visual acuity, IOP1 intraocular pressure before treatment, MOPP1 mean ocular perfusion pressure
before treatment, y years, n number of eyes, SD standard deviation
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Statistical analysis
The descriptive statistics such as the mean value, the
standard deviation, the minimum and maximum
values of age, DBCVA, IOP and MOPP before
treatment in the groups in terms of the stage of
glaucoma were calculated. The assumption of nor-
mality was verified using the Shapiro–Wilk test. The
obtained parameters were analyzed using mixed
model ANOVA (factorial repeated measures
ANOVA). The following parameters: PERG ampli-
tude, peak time, IOP and MOPP, were treated as
dependent variables and the stage of glaucoma as a
categorical factor. It was determined to change each
parameter at two time points before and after therapy
and the interaction of changes over time depending on
the groups (stage of glaucoma). Correlations between
selected parameters were investigated using Pearson
coefficient. Results were considered significant with
p\ 0.05. Data were analyzed using STATISTICA
12.5 software.
Results
The applied therapy significantly decreased IOP in all
eyes, on average 31%. In Fig. 1 changes of the mean
values and its standard errors (whiskers) of the IOP
before and after therapy are shown. The change of the
IOP was significant for both groups, although there
was not significant effect between groups. Mean
ocular perfusion pressure increased in all eyes on
average 14%. Figures 2 and 3 present changes of the
mean values and standard errors of P50 and N95
amplitudes. In Table 2, the mean values before and
after treatment of IOP, MOPP, and PERG amplitudes
of P50 and N95 waves and peak time (PT) of P50 wave
are shown. Significant changes were observed in all
parameters, with an exception of PT P50.
PERG amplitudes of P50 and N95 waves increased
in 75 and 79% eyes, respectively, on average P50 by
28% and N95 by 38%.
The improvement in RGC function, defined as 20%
or more increase in at least one of the PERG waves,
was noticed in 71% of eyes (17/24). In 29% of eyes (7/
24), the PERG amplitudes did not improve.
We did not find any statistical significant correla-
tions between the change of the parameters in time and
stage of glaucoma (Table 3).
For example, PERG examination before and after
treatment from an eye of a 56-year-old woman with an
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Fig. 1 Changes of the mean values and its standard errors
(whiskers) of the IOP before (1) and after (2) therapy. IOP
intraocular pressure
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Fig. 2 Changes of the mean values and its standard errors
(whiskers) of the P50 amplitude before (1) and after (2) therapy.
A amplitude
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improvement in P50 and N95 waves after therapy is
observed.
The characteristics of eyes before and after therapy
are presented in Table 4.
Discussion
The results of this study suggest that approximately
30% IOP reduction in eyes of patients with preperi-
metric and early stages of POAG significantly
improves function of RGC, as registered by the PERG
test.
In evaluating the activity of RGCs before and after
treatment, we used PERG, because it can measure
reversal of RGC dysfunction in glaucomatous eyes
that undergo pharmacological reduction in IOP
[3, 20]. This electrophysiological test reflects not only
RGC apoptosis, but also the dysfunction of other
RGCs that may be reversible, at least in part, after
proper IOP-lowering therapy [20]. The definition of
improvement was framed on the basis of the data from
the literature concerning reproducibility of PERG:
according to Otto and Bach [21], the coefficient of
variation (CV) for transient PERG is 12 ± 2%. That is
why we assumed that, if at least one of the PERG
waves increases after treatment over 20% of the
baseline value, it would strongly suggest an improve-
ment in RGC function. It is in accordance with other
studies [22].
Different mechanisms with an influence on RGC’
function recovery should be considered. To better
understand the role of IOP-lowering therapy,
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Fig. 3 Changes of the mean values and its standard errors
(whiskers) of the N95 amplitude before (1) and after (2) therapy.
A amplitude
Table 2 Values of the
examined parameters before
and after therapy and the
p value of the factorial
repeated measures ANOVA




n number of eyes, SD
standard deviation
Parameter Mean ± SD n Difference ± SD Mean % of change p
A P50 1 (lV) 4.4 ± 1.66 24 -0.94 ± 1.54 27.77 0.0055
A P50 2 (lV) 5.4 ± 1.91
A N95 1 (lV) 5.8 ± 2.38 24 -1.67 ± 1.90 38.28 0.0002
A N95 2 (lV) 7.5 ± 2.57
PT P50 1 (ms) 51.8 ± 3.29 24 -0.43 ± 1.99 1.00 0.3428
PT P50 2 (ms) 52.2 ± 2.48
IOP 1 (mmHg) 24.3 ± 5.72 24 7.82 ± 4.52 30.51 0.0000
IOP 2 (mmHg) 16.4 ± 2.60
MOPP 1 42.4 ± 8.21 24 -5.02 ± 7.18 14.25 0.0031
MOPP 2 47.4 ± 7.22
Table 3 Results of the factorial repeated measures ANOVA,
showing non-interaction between change of the following
parameters in time and stage of glaucoma
Interaction F p
A P50 1.226 0.2801
A N95 2.034 0.1679
PT P50 0.897 0.3538
MOPP 0.164 0.6896
IOP 0.512 0.4820
A amplitude, PT peak time, IOP intraocular pressure, MOPP
mean ocular perfusion pressure
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glaucomatous neurodegeneration must be considered
as a product of multiple factors [23]. Although there
are a number of hypotheses, the entire understanding
of glaucoma pathogenesis has not yet been gained. It is
a combination of 1—axonal insult in the optic nerve
head (ONH) [24], 2—diminished retrograde delivery
of neurotrophins [25], 3—impaired glial cell interac-
tions [26] and 4—local inflammatory response of
astrocytes secreting cytokines [27]. The other mech-
anism playing a role in the glaucoma pathogenesis are:
5—excitotoxicity [28] caused by disruptions in gluta-
mate transport leading to apoptosis of RGCs and 6—
mechanical stress connected with IOP spikes [29] that
increase stiffness in the trabecular meshwork. These
last two processes are unlikely to have a real effect on
RGCs’ recovery in this trial, because the time of
therapy was too short to let them operate.
The first reason why RGCs’ function improvement
was possible is that, if restored to normal values, IOP
stops deforming the tissues building ONH. Lower
translaminar pressure, defined as a difference between
IOP and intracranial pressure (ICP), facilitated axo-
plasmal flow, so the transport of intracellular nutrients,
protein biosynthesis and glycolysis was possible. Such
RGCs acquired a new chance to improve metabolism.
We can also admit that lower IOP allowed retrograde
transport of neurotrophins, which are necessary for
differentiation, regeneration and development of
RGCs. It is also possible that reduction in astrocytic
interleukin secretion (ex. tumor necrosis factor-TNF)
contributed to RGC function improvement. Cytokine
biosynthesis is induced by different impulses (here
increased IOP), and their half-life in the blood is short.
Possibly, after IOP reduction, their concentration
diminished to the level that no longer damaged RGC
axons, and improvement in their function was
possible.
In the presented study, the improvement in RGC
function was noticed in 71% of eyes (17/24). In 29% of
eyes (7/24), the PERG amplitudes did not improve.
Our results show that the amplitude of the N95 wave
had the most significant increase after IOP-lowering
therapy, because it is represented mainly by RGCs, in
contrast to the amplitude of the P50 wave, which is
generated as well by cones and cone bipolar cells of
the macula region [30]. Peak time of P50 did not
statistically change before and after treatment. There
were no interactions between the change of PERG
parameters in time and type of glaucoma, as presented
in Table 3. Other researchers also did not find such
correlations [20]: probably, the relationship between
these parameters is complex, and perhaps, the wide
range of normal values for PERG test prevents
creating such linear relationships. Possibly, these
two glaucoma groups were too small to detect such
interdependences.
In 29% of the eyes, although an IOP reduction by
near 30% was achieved, the function of RGCs did not
improve. The statistical differences between the group
with and without improvement were not possible to
establish, except lower baseline amplitudes of P50 and
N95 waves in these eyes, which improved. Perhaps,
the influence of IOP reduction is easier to prove in the
eyes with worse function initially, because the number
of dysfunctional RGCs is higher than in the eyes with
PERG amplitudes around normal values. It is well
known that increased IOP can influence RGC function
not in the same way: an extreme example is patients
with normal tension glaucoma, who suffer from
glaucomatous neuropathy, despite good levels of
IOP, in contrast to ocular hypertension patients, in
whom the risk of developing glaucoma is only 1% per
year [31].
We realize this study has limitations: the two
groups are too small to draw general conclusions, and
in the future, a larger sample of patients with untreated
preperimetric and early-stage POAG will be recom-
mended to test. In conclusion, our results strongly
Fig. 4 Example of PERG amplitude of P50 and N95 waves
improvement after treatment (A after treatment, B before
therapy). A amplitude, t time
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suggest that RGC function may be improved after IOP
reduction by around 30%. For a chosen group of
patients, hindering progression of glaucomatous neu-
ropathy is possible through restoration of some RGCs
to normal function. Wide range of therapeutic possi-
bilities providing IOP reduction, including topical
drug combinations, laser procedures and minimally
invasive glaucoma surgery (MIGS), should be recom-
mended to these selected glaucoma patients. Probably,
in the group where the treatment did not improve RGC
function, destruction and apoptosis of these cells is
dominating, and perhaps, in these patients’ eyes, IOP-
lowering therapy is less important. Pattern elec-
troretinogram can be a useful test to monitor changes
of RGC function in treated patients with POAG.
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Table 4 Characteristics of eyes before and after treatment


















1 33.5 3.68 3.55 47.5 33.39 14.6 4.55 6.26 50.9 48.73
2 19.6 4.41 6.39 51.4 51.73 12.9 6.79 8.86 51.9 48.43
3 23 3.36 4.37 53.3 56.78 16.2 4.74 6.82 55.8 66.47
4 19.4 3.82 5.15 54.8 34.82 14.3 5 7.03 52.3 45.03
5 24.8 2.26 3.39 53.8 41.64 18.2 3.38 4.5 55.3 50.24
6 19.6 7.37 10.4 53.3 36.40 13.5 8.11 11.4 52.8 47.17
7 16.9 5.14 7.19 51.4 35.54 12.9 9.35 13.2 50.9 39.77
8 21 2.57 3.34 59.7 46.33 13.3 3.5 4.97 59.2 45.37
9 28.8 4.47 7.51 49.9 28.98 18.7 6.89 9.08 51.4 37.08
10 23.5 7.66 9.02 52.3 43.39 15.2 6.68 9.63 51.4 42.80
11 24.7 5.27 6.62 50.9 44.19 14.6 5.19 7.22 53.3 44.73
12 25.9 2.86 2.29 54.8 39.88 19 4.69 6.52 52.8 42.78
13 21.5 1.32 3.09 49.9 47.39 14.8 2.15 5.5 50.9 52.31
14 34.6 5.06 7.17 52.3 46.07 21.8 7.71 10.3 53.8 50.20
15 24.8 5.71 6.92 56.3 57.87 19.8 8.38 10.7 52.3 42.42
16 15.9 3.44 5.14 50.4 44.10 13 3.13 4.63 50.9 49.00
17 21.9 6.62 10.1 50.4 42.54 17.5 6.43 7.87 51.9 54.28
18 34.9 4.46 5.05 50.9 46.66 20.5 4.52 7 51.4 59.50
19 25.7 4.27 4.32 51.9 47.63 19 3.08 4.32 51.9 53.44
20 22.4 6.4 8.91 48.4 25.38 18 5.79 8.81 47.5 30.67
21 20.7 6.4 7.7 51.9 43.74 15.7 3.89 5.95 51.9 49.19
22 21.3 2.92 3.1 53.3 46.92 16.1 4.83 4.58 51.4 42.34
23 20.7 3.47 6.65 42.1 46.41 17.7 6.48 11 47 47.86
24 37.2 2.94 2.95 52.5 29.24 17.4 3.19 4.21 54.8 47.71
IOP intraocular pressure, MOPP mean ocular perfusion pressure, A amplitude, PT peak time
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